Biogen (BIIB) | Stock Overview & Key Data

What is BIIB's 52-week high and low?

In the last 52 weeks, Biogen reached a high of $238.00 (on July 12, 2024) and a low of $110.04 (on April 9, 2025).

What is the market cap and P/E ratio for BIIB?

Curious about Biogen's size and valuation? Its market capitalization stands at 18.28B. When it comes to valuation, the P/E ratio (trailing twelve months) is 12.33, and the forward P/E (looking ahead) is 7.49.

Does BIIB pay dividends? If so, what's the yield?

As for dividends, Biogen isn't currently offering a significant yield, or that specific data isn't available right now.

Who are Biogen's main competitors or similar companies to consider before investing?

When looking at Biogen, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Eli Lilly and LLY	691.83B	Healthcare	Drug Manufacturers - General	-14.64%	136.23%
Johnson & Johnson JNJ	364.09B	Healthcare	Drug Manufacturers - General	6.51%	-12.49%
Merck & Co MRK	198.52B	Healthcare	Drug Manufacturers - General	-36.00%	-12.77%
Amgen AMGN	146.49B	Healthcare	Drug Manufacturers - General	-4.07%	20.03%
Gilead Sciences GILD	132.09B	Healthcare	Drug Manufacturers - General	67.57%	77.83%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Biogen Inc.? (e.g., ROE, Debt/Equity)

To get a sense of Biogen's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 9.19%, the Debt to Equity ratio from the most recent quarter is 39.00, and its Gross Profit Margin stands at 74.11%.

What is the recent revenue and earnings growth for BIIB?

Looking at Biogen's growth, its revenue over the trailing twelve months (TTM) was $10B. Compared to the same quarter last year (YoY), quarterly revenue grew by 6.10%, and quarterly earnings saw a YoY growth of -38.90%.

How much of BIIB stock is held by insiders and institutions?

Wondering who owns Biogen stock? Company insiders (like executives and directors) hold about 0.22% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 92.93%.

For more common questions about our data, please visit our About Data page.